로딩 중…
지수 로딩 중…
Fulcrum Therapeutics, Inc.
FULC· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$3.71+3.63%
2026-08-03
Financials
Valuation Metrics
Fulcrum Therapeutics, Inc.'s Market Cap is $247M. At end of 2025 it was $717M. Ranked #3005 of 3,112 in US market (top 97%), #1361 of 1,445 on NASDAQ (top 94%), #249 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $247M | US#3,005/3,112 Sec#249/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-85M | US—/3,112 Sec—/269 |
| Total Assets | $324M | US#2,878/3,112 Sec#202/269 |
| Net Assets | $311M | US#2,530/3,112 Sec#156/269 |
| Value | ||
| P/B | 0.80x | US#204/3,112 Sec#7/269 |
| FCF Yield | -26.76% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -27.36% | US#2,592/3,112 Sec#119/269 |
| ROA | -26.24% | US#2,838/3,112 Sec#148/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 4.27% | US#38/3,112 Sec#13/269 |
| Total Debt | $5M | US#2,847/3,112 Sec#217/269 |
| FCF | $-66M | US#2,513/3,112 Sec#124/269 |
| Cash | $48M | US#2,600/3,112 Sec#231/269 |
| Current Ratio | 31.35x | US#78/3,112 Sec#7/269 |
| Performance | ||
| 1Y Return | -45.68% | US#2,944/3,112 Sec#241/269 |
| 1M Return | -3.39% | US#2,067/3,112 Sec#108/269 |
| From 52W High | -76.43% | US#3,070/3,112 Sec#264/269 |
| 1Y MDD | -78.49% | US#3,033/3,112 Sec#258/269 |
| Trading | ||
| Volume | 2,239,157 shares | US#811/3,112 Sec#72/269 |
| Trading Value | $8M | US#2,447/3,112 Sec#195/269 |
| Per Share | ||
| EPS | $-1.18 | US—/3,112 Sec—/269 |
| BPS | $5.51 | US#2,180/3,112 Sec#124/269 |